Nervana Medical | Sandy, Utah
If you’ve spent any time on social media or in fitness, sports medicine, or regenerative health spaces, you may have heard about BPC-157. It’s often described online as a “healing peptide” and is frequently marketed for injury recovery, tissue repair, or inflammation.
With so much information and misinformation circulating, we believe patients deserve a clear, honest explanation of what is known, what is not, and where the science currently stands.
What Is BPC-157?
BPC-157 is a synthetic pentadecapeptide (a short chain of amino acids) derived from a sequence found in human gastric juice. It was originally studied for its potential role in protecting and healing gastrointestinal tissue.
Over time, interest expanded as laboratory and animal studies suggested possible effects on wound healing, inflammation, blood vessel formation, and tissue repair across many organ systems.
It is important to note: BPC-157 is not an FDA-approved medication and is not approved for any medical indication in humans.
What Does the Research Actually Show?
Extensive Preclinical (Animal) Research
In animal and laboratory studies, BPC-157 has demonstrated effects on healing in tissues such as:
- Skin, muscle, tendon, and ligament
- Bone and joints
- Gastrointestinal tract
- Blood vessels and nerves
Proposed mechanisms include:
- Modulation of inflammation
- Effects on angiogenesis (new blood vessel formation)
- Interaction with nitric oxide signaling
- Influence on growth-related pathways
These findings are scientifically interesting, but they remain preclinical, meaning they have not been reliably demonstrated in humans.
What Human Data Exists?
This is where the evidence becomes very limited.
- There are no large, randomized, controlled human clinical trials demonstrating safety or efficacy.
- A small number of uncontrolled case series and pilot studies have been published, involving very small patient groups without comparison controls.
- While some participants reported symptom improvement, these studies lack the rigor required to establish true clinical benefit or long-term safety.
In medicine, animal data does not reliably predict how a therapy will work or whether it is safe in humans (even though sometimes humans act like animals)!
Is BPC-157 Safe?
BPC-157 appears to have a favorable safety profile in animal studies, with minimal reported toxicity. However:
- Long-term human safety data does not exist
- Optimal dosing in humans is unknown
- Drug–drug interactions have not been adequately studied
- Manufacturing is often unregulated, raising concerns about purity, contamination, and dosing accuracy
A lack of reported harm is not the same as proven safety.
Regulatory and Ethical Considerations
- BPC-157 is not approved by the Food and Drug Administration
- It is not recognized as a legitimate prescription medication
- Its sale often occurs through compounding or research-chemical channels without standardized oversight
- Use has been restricted in professional sports settings, including scrutiny from organizations such as the World Anti-Doping Agency. The World Anti-Doping Agency temporarily banned BPC-157 in 2022 (though it is not currently listed as banned), and its use remains prohibited in professional sports
These factors raise important ethical and legal considerations for both patients and clinicians.
Why Is BPC-157 So Popular Right Now?
Many patients are frustrated by:
- Chronic injuries
- Slow recovery
- Persistent inflammation
- Limited answers from conventional care
Nervana Medical’s Position
We believe patients deserve honest conversations with providers who understand potential risks and benefits and are committed to staying in the know on the latest and greatest of healthcare and health trends.
If You’re Curious About BPC-157
If you are considering or have questions about BPC-157, we encourage you to:
- Discuss your symptoms and goals with a licensed medical provider
- Be cautious about self-injecting or sourcing peptides online
- Focus on therapies with established safety profiles and human clinical data
- Ask questions about evidence, regulation, and long-term outcomes
The Bottom Line
BPC-157 is an interesting compound with extensive animal research and very limited human data. At this time, it remains an experimental substance. If you’re navigating chronic pain, injury recovery, or inflammation, we’re here to help you explore a variety of treatment modalities and interventions.
As of 2024, approximately 85-100 peptide therapeutics have been approved by the FDA, with the exact number varying based on classification criteria (whether to include peptide-antibody conjugates, biosimilars, and oligonucleotides).
If you want to learn more about peptides, from what they do to which ones are FDA approved, schedule a peptide consult!
References
Al Musaimi, O. (2024). Exploring FDA-approved frontiers: Insights into natural and engineered peptide analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH realms. Biomolecules, 14(3), 264. https://doi.org/10.3390/biom14030264
Al Musaimi, O. (2024). Peptide therapeutics: Unveiling the potential against cancer—a journey through 1989. Cancers, 16(5), 1032. https://doi.org/10.3390/cancers16051032
Al Musaimi, O. (2024). FDA’s stamp of approval: Unveiling peptide breakthroughs in cardiovascular diseases, ACE, HIV, CNS, and beyond. Journal of Peptide Science, 30(11), e3627. https://doi.org/10.1002/psc.3627
Al Musaimi, O., AlShaer, D., de la Torre, B. G., & Albericio, F. (2025). 2024 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals, 18(3), 291. https://doi.org/10.3390/ph18030291
Al Shaer, D., Al Musaimi, O., Albericio, F., & de la Torre, B. G. (2024). 2023 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals, 17(2), 243. https://doi.org/10.3390/ph17020243
Al Musaimi, O., Al Shaer, D., Albericio, F., & de la Torre, B. G. (2023). 2022 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals, 16(3), 336. https://doi.org/10.3390/ph16030336
Al Musaimi, O., Al Shaer, D., Albericio, F., & de la Torre, B. G. (2021). 2020 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals, 14(2), 145. https://doi.org/10.3390/ph14020145
Al Shaer, D., Al Musaimi, O., Albericio, F., & de la Torre, B. G. (2020). 2019 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals, 13(3), E40. https://doi.org/10.3390/ph13030040
Jain, S., Gupta, S., Patiyal, S., & Raghava, G. P. S. (2024). THPdb2: Compilation of FDA-approved therapeutic peptides and proteins. Drug Discovery Today, 29(7), 104047. https://doi.org/10.1016/j.drudis.2024.104047
Józwiak, M., Bauer, M., Kamysz, W., & Kleczkowska, P. (2025). Multifunctionality and possible medical application of the BPC 157 peptide—Literature and patent review. Pharmaceuticals, 18(2), 185. https://doi.org/10.3390/ph18020185
Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC-157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4), 8–13.
Lee, E., Walker, C., & Ayadi, B. (2024). Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine, 30(10), 12–17.
Mayfield, C. K., Bolia, I. K., Feingold, C. L., et al. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. The American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593
Murugan, N. A., Raja, K. M. P., & Saraswathi, N. T. (2021). Peptide-based antiviral drugs. In Advances in Experimental Medicine and Biology (Vol. 1322, pp. 261–284). Springer. https://doi.org/10.1007/978-981-16-0267-2_10
Seiwerth, S., Milavić, M., Vukojević, J., et al. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology, 12, 627533. https://doi.org/10.3389/fphar.2021.627533
Sikiric, P., Rucman, R., Turkovic, B., et al. (2018). BPC 157 and standard angiogenic growth factors: Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Current Pharmaceutical Design, 24(18), 1972–1989. https://doi.org/10.2174/1381612824666180712110447
Sikiric, P., Rucman, R., Turkovic, B., et al. (2018). Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157: Vascular recruitment and gastrointestinal tract healing. Current Pharmaceutical Design, 24(18), 1990–2001. https://doi.org/10.2174/1381612824666180608101119
Sikiric, P., Seiwerth, S., Rucman, R., et al. (2012). Focus on ulcerative colitis: Stable gastric pentadecapeptide BPC 157. Current Medicinal Chemistry, 19(1), 126–132. https://doi.org/10.2174/092986712803414015
Sikiric, P., Seiwerth, S., Skrtic, A., et al. (2025). BPC 157 therapy: Targeting angiogenesis and nitric oxide’s cytotoxic and damaging actions, but maintaining, promoting, or recovering their essential protective functions. Pharmaceuticals, 18(10), 1450. https://doi.org/10.3390/ph18101450
Sikiric, P., Skrtic, A., Gojkovic, S., et al. (2022). Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia–reperfusion injury following Pringle maneuver, and Budd–Chiari syndrome. World Journal of Gastroenterology, 28(1), 23–46. https://doi.org/10.3748/wjg.v28.i1.23
Usmani, S. S., Bedi, G., Samuel, J. S., et al. (2017). THPdb: Database of FDA-approved peptide and protein therapeutics. PLOS ONE, 12(7), e0181748. https://doi.org/10.1371/journal.pone.0181748
Vasireddi, N., Hahamyan, H., Salata, M. J., et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal. Advance online publication. https://doi.org/10.1177/15563316251355551
U.S. Food and Drug Administration. (.d.). FDA Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/